Immunotherapy in the First-Line Setting in Wild-Type NSCLC.

Area of Science:

• Oncology
• Pulmonology
• Immunotherapy

Background:

• Treatment for advanced non-small cell lung cancer (NSCLC) is rapidly evolving with new therapies.
• Immunotherapy has shown significant efficacy improvements in first-line stage IV NSCLC.

Purpose of the Study:

• To review current data on immunotherapy use in first-line stage IV NSCLC.
• To organize findings by treatment strategy: single-agent immunotherapy, immunotherapy plus chemotherapy, dual immunotherapy, and dual immunotherapy plus chemotherapy.

Main Methods:

• Systematic review of clinical trial data.
• Tabulation of efficacy results.
• Analysis of treatment application based on programmed death-ligand 1 (PD-L1) expression levels.

Main Results:

• Single checkpoint inhibitors are effective for NSCLC with high PD-L1 expression.
• Adding chemotherapy to immunotherapy demonstrates patient benefit.
• Immunotherapy, with or without chemotherapy, is the standard of care for first-line stage IV NSCLC lacking EGFR, ALK, or ROS driver mutations.

Conclusions:

• Immunotherapy represents a major advancement in first-line treatment for advanced NSCLC.
• Treatment decisions should consider PD-L1 expression levels and combination strategies.
• Further research continues to refine optimal therapeutic algorithms for NSCLC.